Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model.
Inhye E AhnXin TianDavid IpeMei ChengMaher AlbitarL Claire TsaoLei ZhangWanlong MaSarah E M HermanErika M GaglioneSusan SotoJames P DeanAdrian WiestnerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
Patients at increased risk of ibrutinib failure can be identified at treatment initiation and considered for clinical trials.